Lyell Immunopharma Inc. Common Stock

Lyell Immunopharma Inc. a clinical-stage cell therapy company engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies such as c-Jun overexpression and NR4A3 gene knockout to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies including Epi-R to generate population of T cells with durable stemness and Stim-R a proprietary synthetic cell mimetic. The company's pipeline includes LYL797 a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845 an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119 a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco California.